XW043G4 – Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
Coding Notes
Active
Billable, valid for HIPAA-covered transactions
PCS Table
Section
X
New Technology
|
|||
Body System
W
Anatomical Regions
|
|||
Operation
0
Introduction
|
|||
Body Part | Approach | Device / Substance / Technology | Qualifier |
0
Skin
|
X
External
|
2
Bromelain-enriched Proteolytic Enzyme
|
7
New Technology Group 7
|
1
Subcutaneous Tissue
|
3
Percutaneous
|
9
Satralizumab-mwge
|
7
New Technology Group 7
|
1
Subcutaneous Tissue
|
3
Percutaneous
|
F
Other New Technology Therapeutic Substance
|
5
New Technology Group 5
|
1
Subcutaneous Tissue
|
3
Percutaneous
|
H
Other New Technology Monoclonal Antibody
K
Leronlimab Monoclonal Antibody
S
COVID-19 Vaccine Dose 1
T
COVID-19 Vaccine Dose 2
U
COVID-19 Vaccine
|
6
New Technology Group 6
|
1
Subcutaneous Tissue
|
3
Percutaneous
|
W
Caplacizumab
|
5
New Technology Group 5
|
1
Subcutaneous Tissue
|
X
External
|
2
Bromelain-enriched Proteolytic Enzyme
|
7
New Technology Group 7
|
2
Muscle
|
3
Percutaneous
|
S
COVID-19 Vaccine Dose 1
T
COVID-19 Vaccine Dose 2
U
COVID-19 Vaccine
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
0
Brexanolone
2
Nerinitide
3
Durvalumab Antineoplastic
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
5
Narsoplimab Monoclonal Antibody
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
6
Lefamulin Anti-infective
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
6
Terlipressin
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
7
Coagulation Factor Xa, Inactivated
|
2
New Technology Group 2
|
3
Peripheral Vein
|
3
Percutaneous
|
7
Trilaciclib
8
Lurbinectedin
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
9
Defibrotide Sodium Anticoagulant
|
2
New Technology Group 2
|
3
Peripheral Vein
|
3
Percutaneous
|
9
Ceftolozane/Tazobactam Anti-infective
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
A
Bezlotoxumab Monoclonal Antibody
|
3
New Technology Group 3
|
3
Peripheral Vein
|
3
Percutaneous
|
A
Cefiderocol Anti-infective
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
A
Ciltacabtagene Autoleucel
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
B
Cytarabine and Daunorubicin Liposome Antineoplastic
|
3
New Technology Group 3
|
3
Peripheral Vein
|
3
Percutaneous
|
B
Omadacycline Anti-infective
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
B
Amivantamab Monoclonal Antibody
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
C
Eculizumab
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
C
Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
D
Atezolizumab Antineoplastic
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
E
Remdesivir Anti-infective
|
5
New Technology Group 5
|
3
Peripheral Vein
|
3
Percutaneous
|
E
Etesevimab Monoclonal Antibody
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
F
Other New Technology Therapeutic Substance
|
3
New Technology Group 3
|
3
Peripheral Vein
|
3
Percutaneous
|
F
Other New Technology Therapeutic Substance
|
5
New Technology Group 5
|
3
Peripheral Vein
|
3
Percutaneous
|
F
Bamlanivimab Monoclonal Antibody
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
G
Plazomicin Anti-infective
|
4
New Technology Group 4
|
3
Peripheral Vein
|
3
Percutaneous
|
G
Sarilumab
|
5
New Technology Group 5
|
3
Peripheral Vein
|
3
Percutaneous
|
G
REGN-COV2 Monoclonal Antibody
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
G
Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
H
Synthetic Human Angiotensin II
|
4
New Technology Group 4
|
3
Peripheral Vein
|
3
Percutaneous
|
H
Tocilizumab
|
5
New Technology Group 5
|
3
Peripheral Vein
|
3
Percutaneous
|
H
Other New Technology Monoclonal Antibody
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
H
Axicabtagene Ciloleucel Immunotherapy
J
Tisagenlecleucel Immunotherapy
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
K
Fosfomycin Anti-infective
|
5
New Technology Group 5
|
3
Peripheral Vein
|
3
Percutaneous
|
K
Idecabtagene Vicleucel Immunotherapy
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
L
CD24Fc Immunomodulator
|
6
New Technology Group 6
|
3
Peripheral Vein
|
3
Percutaneous
|
L
Lifileucel Immunotherapy
M
Brexucabtagene Autoleucel Immunotherapy
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
N
Meropenem-vaborbactam Anti-infective
|
5
New Technology Group 5
|
3
Peripheral Vein
|
3
Percutaneous
|
N
Lisocabtagene Maraleucel Immunotherapy
|
7
New Technology Group 7
|
3
Peripheral Vein
|
3
Percutaneous
|
Q
Tagraxofusp-erzs Antineoplastic
S
Iobenguane I-131 Antineoplastic
U
Imipenem-cilastatin-relebactam Anti-infective
W
Caplacizumab
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
0
Brexanolone
2
Nerinitide
3
Durvalumab Antineoplastic
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
5
Narsoplimab Monoclonal Antibody
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
6
Lefamulin Anti-infective
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
6
Terlipressin
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
7
Coagulation Factor Xa, Inactivated
|
2
New Technology Group 2
|
4
Central Vein
|
3
Percutaneous
|
7
Trilaciclib
8
Lurbinectedin
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
9
Defibrotide Sodium Anticoagulant
|
2
New Technology Group 2
|
4
Central Vein
|
3
Percutaneous
|
9
Ceftolozane/Tazobactam Anti-infective
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
A
Bezlotoxumab Monoclonal Antibody
|
3
New Technology Group 3
|
4
Central Vein
|
3
Percutaneous
|
A
Cefiderocol Anti-infective
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
A
Ciltacabtagene Autoleucel
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
B
Cytarabine and Daunorubicin Liposome Antineoplastic
|
3
New Technology Group 3
|
4
Central Vein
|
3
Percutaneous
|
B
Omadacycline Anti-infective
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
B
Amivantamab Monoclonal Antibody
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
C
Eculizumab
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
C
Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
D
Atezolizumab Antineoplastic
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
E
Remdesivir Anti-infective
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
E
Etesevimab Monoclonal Antibody
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
F
Other New Technology Therapeutic Substance
|
3
New Technology Group 3
|
4
Central Vein
|
3
Percutaneous
|
F
Other New Technology Therapeutic Substance
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
F
Bamlanivimab Monoclonal Antibody
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
G
Plazomicin Anti-infective
|
4
New Technology Group 4
|
4
Central Vein
|
3
Percutaneous
|
G
Sarilumab
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
G
REGN-COV2 Monoclonal Antibody
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
G
Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
H
Synthetic Human Angiotensin II
|
4
New Technology Group 4
|
4
Central Vein
|
3
Percutaneous
|
H
Tocilizumab
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
H
Other New Technology Monoclonal Antibody
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
H
Axicabtagene Ciloleucel Immunotherapy
J
Tisagenlecleucel Immunotherapy
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
K
Fosfomycin Anti-infective
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
K
Idecabtagene Vicleucel Immunotherapy
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
L
CD24Fc Immunomodulator
|
6
New Technology Group 6
|
4
Central Vein
|
3
Percutaneous
|
L
Lifileucel Immunotherapy
M
Brexucabtagene Autoleucel Immunotherapy
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
N
Meropenem-vaborbactam Anti-infective
|
5
New Technology Group 5
|
4
Central Vein
|
3
Percutaneous
|
N
Lisocabtagene Maraleucel Immunotherapy
|
7
New Technology Group 7
|
4
Central Vein
|
3
Percutaneous
|
Q
Tagraxofusp-erzs Antineoplastic
S
Iobenguane I-131 Antineoplastic
U
Imipenem-cilastatin-relebactam Anti-infective
W
Caplacizumab
|
5
New Technology Group 5
|
9
Nose
|
7
Via Natural or Artificial Opening
|
M
Esketamine Hydrochloride
|
5
New Technology Group 5
|
D
Mouth and Pharynx
|
X
External
|
6
Lefamulin Anti-infective
|
6
New Technology Group 6
|
D
Mouth and Pharynx
|
X
External
|
8
Uridine Triacetate
|
2
New Technology Group 2
|
D
Mouth and Pharynx
|
X
External
|
F
Other New Technology Therapeutic Substance
J
Apalutamide Antineoplastic
L
Erdafitinib Antineoplastic
|
5
New Technology Group 5
|
D
Mouth and Pharynx
|
X
External
|
M
Baricitinib
|
6
New Technology Group 6
|
D
Mouth and Pharynx
|
X
External
|
R
Venetoclax Antineoplastic
T
Ruxolitinib
V
Gilteritinib Antineoplastic
|
5
New Technology Group 5
|
G
Upper GI
H
Lower GI
|
7
Via Natural or Artificial Opening
|
M
Baricitinib
|
6
New Technology Group 6
|
G
Upper GI
H
Lower GI
|
8
Via Natural or Artificial Opening Endoscopic
|
8
Mineral-based Topical Hemostatic Agent
|
6
New Technology Group 6
|
Q
Cranial Cavity and Brain
|
3
Percutaneous
|
1
Eladocagene exuparvovec
|
6
New Technology Group 6
|
V
Bones
|
0
Open
|
P
Antibiotic-eluting Bone Void Filler
|
7
New Technology Group 7
|